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AT A GLANCE
O steoarthritis (OA) refers to a clinical syndrome of joint pain accompanied by varying degrees of functional limitation and 
reduced quality of life (National Institute for 
Health and Care Excellence (NICE), 2014).  
The most affected peripheral joints are the 
knees, hips, and small hand joints. Pain, reduced 
function, and effects on a person’s ability to 
carry out their day-to-day activities can be 
important consequences. Pain in itself is also a 
complex biopsychosocial issue, related in part 
to a person’s expectations and self-efficacy (that 
is, their belief in their ability to complete tasks 
and reach goals), and is associated with changes 
in mood, sleep and coping abilities. There is 
often a poor link between changes visible 
on an X-ray and symptoms of osteoarthritis: 
minimal changes can be associated with a 
lot of pain, or modest structural changes to 
joints can occur with minimal accompanying 
symptoms. Contrary to popular belief, OA is 
not caused by ageing and does not necessarily 
deteriorate (NICE, 2014).
Epidemiology and risk factors
OA is the most prevalent form of arthritis and 
a leading cause of pain and disability worldwide 
(NICE, 2014; O’Neill et al, 2018; Vina and 
Kwoh, 2018). It affected 303 million people 
globally in 2017 (James et al, 2018). In the UK 
approximately 8.5 million people have joint 
pain related to OA (NICE, 2014). A recent 
review by Kloppenburg and Berenbaum (2020) 
suggested that epidemiological studies are 
needed to confirm premature mortality in OA 
and its associated physical disabilities. 
OA involves degradation of the articular 
cartilage, synovium, and subchondral bones 
causing joint pain, functional limitation and 
reduced quality of life (Cooper et al, 2013). 
OA can affect any joint. The knee, hip, 
hand and spine are the most common sites 
of OA—Deshpande et al (2016) estimated 
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that 14 million people in the USA have 
symptomatic knee OA—but it can also occur in 
the ankles and wrists (Arden and Nevitt, 2006).
The UK Clinical Practice Research 
Datalink (CPRD) comprising data on nearly 
17.5 million patients was used for a UK 
prevalence of osteoarthritis study (Swain et 
al, 2020). The standardised incidence of any 
OA in 2017 was 6.8 per 1000 person-years 
(95% CI 6.7 to 6.9) and prevalence was 10.7% 
(95% CI 10.7–10.8%). Both incidence and 
prevalence were higher in women than men. 
The incidence of any OA decreased gradually 
over 20 years at an annual rate of −1.6% 
(95%CI -2.0 to −1.1%), and the reduction 
was faster for people born after 1960. The 
prevalence of any OA increased gradually at 
an annual rate of 1.4% (95% CI 1.3–1.6%). 
Although the prevalence was highest in 
Scotland and Northern Ireland, incidence was 
highest in the East Midlands. Both incidence 
and prevalence reported highest in the knee 
followed by hip, wrist/hand, and ankle/foot.
The risk factors for OA can be divided into 
person-level factors, such as age, sex, obesity, 
genetics, race/ethnicity and diet, and joint-level 
factors including injury, malalignment and 
abnormal loading of the joints (Johnson and 
Hunter, 2014). Age is the single greatest risk 
factor for the development of OA (Shane-
Anderson and Loeser, 2010). Women are at 
greater risk of OA and women have more 
severe symptoms than men, especially after 
menopausal age (Srikanth et al, 2005). Other 
risk factors associated with OA can be seen in 
Box 1 (Harris and Crawford, 2019).
Osteoarthritis characteristics  
and diagnosis
OA is characterised pathologically by localised 
loss of cartilage, remodelling of adjacent bone 
and associated inflammation (NICE, 2014). A 
variety of traumas may trigger the need for a 
joint to repair itself. OA includes a slow but 
efficient repair process that often compensates 
for the initial trauma, resulting in a structurally 
altered but symptom-free joint. In some 
people, because of either overwhelming trauma 
or compromised repair, the process cannot 
compensate, resulting in eventual presentation 
with symptomatic OA; this might be thought 
of as ‘joint failure’. This in part explains the 
extreme variability in clinical presentation and 
outcome that can be observed between people, 
and at different joints in the same person.
OA can be diagnosed clinically, 
pathologically, or radiographically (Zhang 
and Jordan, 2010). Primarily, clinicians may 
define OA by examining the patient’s signs and 
symptoms, and risk factors. According to the 
NICE (2014) OA guidelines: 
‘OA should be diagnosed clinically 
without investigations if a person: is 45 
or over and has activity-related joint 
pain and has no morning joint-related 
stiffness, or morning stiffness that lasts 
no longer than 30 minutes.’
Laboratory testing such as inflammatory 
markers are not usually required to diagnose 
OA. Generally, inflammatory markers, such as 
erythrocyte sedimentation rate and C-reactive 
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Box 1. Risk factors for osteoarthritis
 ■ Age
 ■ Female gender
 ■ Obesity
 ■ Lack of osteoporosis
 ■ Occupation
 ■ Participation in sports
 ■ Previous injury
 ■ Muscle weakness
 ■ Proprioceptive deficits
 ■ Family history of osteoarthritis
 ■ Acromegaly
 ■ Calcium crystal deposition
Source: Harris and Crawford, 2019
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protein level, are normal in OA patients 
(Sinusas, 2012). Radiography such as plain 
X-rays could be used to confirm the diagnosis. 
The most common radiographic grading 
system for OA is the Kellgren and Lawrence 
grade, which scores the severity on a scale 
of 0 to 4. A score of 2 or above in Kellgren 
and Lawrence indicates definite radiographic 
osteoarthritis (Kellgren et al, 1963).
Recommendations for practice
The Osteoarthritis Research Society 
International has stated the goals of OA 
management include pain management and 
optimal functional ability. To that end, it 
has updated and expanded on its guidelines 
regarding the management of OA of the 
hip and knee by developing patient-focused 
treatment recommendations for individuals 
with knee, hip, and polyarticular OA that are 
derived from expert consensus and based on 
objective review of high-quality meta-analytic 
data (Bannuru et al, 2019).
European League Against Rheumatism 
(EULAR) recommendations for the health 
professional’s approach to pain management 
in inflammatory arthritis and osteoarthritis 
are guided by expert opinion and partly 
underpinned by a considerable number of 
systematic reviews and meta-analyses. An 
expert group developed and launched the first 
set of recommendations that enable health 
professionals to provide knowledgeable and 
evidence-based pain-management support for 
people with inflammatory arthritis and OA 
(Geenan et al, 2018) (Figure 1).
Since there is as yet no cure for OA, 
the management of risks and predisposing 
factors is vital in delaying disease progression. 
The treatments that are currently available 
for OA are aiming for pain reduction, 
correcting deformities, and improving 
joint function to improve the quality of 
the patient’s life (NICE, 2014). Nurses 
have a vital role in reducing the pain and 
disability caused by OA. In 2011, an OA 
symposium convened experts in areas of 
nursing, epidemiology, rheumatology, public 
policy, geriatrics, pharmacotherapy, physical 
therapy, and complementary modalities to 
discuss the importance of nurses in reducing 
the disability caused by OA (Robbins and 
Kulesa, 2012). The symposium produced 
five important themes to be considered: 
knowledge of OA burden, OA national 
initiatives to help raise awareness, risk and 
progression assessment for OA, interventions 
to relieve OA symptoms, and minimising 
progression/self-management support. 
These themes emphasise that there is 
no single treatment that can work for 
all. OA management must incorporate 
different treatment options, primarily non-
pharmacological, then pharmacological, and 
finally surgical interventions.
Non-pharmacological
Non-pharmacological treatments for OA 
include patient education, exercise, weight 
loss, and physiotherapy (Geenan et al, 
2018). NICE (2014) recommends that the 
non-pharmacological treatments should be 
considered for all OA patients irrespective of 
age, comorbidity, pain severity or disability. 
Although they may show a limited effect 
in reducing symptoms, one of their main 
advantages is that they pose no inherent risks 
(Scott and Kowalczyk, 2007).
NICE (2014) advises people with 
osteoarthritis to exercise as a core treatment 
irrespective of age, comorbidity, pain severity 
or disability. Exercise should include local 
muscle strengthening and general aerobic 
fitness. It has not been specified whether 
exercise should be provided by the NHS 
or whether the health professional should 
provide advice and encouragement to 
the person to obtain and carry out the 
intervention themselves. Exercise has been 
found to be beneficial, but the clinician needs 
to make a judgement in each case on how 
to effectively ensure participation. This will 
depend on the person’s individual needs, 
circumstances and self-motivation, and the 
availability of local facilities. Manipulation 
and stretching should be considered as an 
adjunct to core treatments, particularly for 
osteoarthritis of the hip. 
Drug therapy
Several non-pharmacological and 
pharmacological measures are available, either 
individually or in combination, for treating 
the widespread disease and public health 
issue that is OA. Only some of those patients 
with radiologically detectable OA will 
actually suffer clinically relevant symptoms. 
However, when the arthritis becomes 
symptomatic and painful, drug therapy can 
then be useful. According to Steinmeyer 
et al (2018) pharmaceuticals represent an 
essential pillar of therapy, and a wide range 
of very different drugs, especially non-
steroidal anti-inflammatory drugs (NSAIDs) 
in combination with other medications (eg 
proton pump inhibitors), opioid analgesics, 
potentially cartilage active agents and 
phytopharmaceuticals, have all found use. 
Topical agents are also popular since they 
exert fewer systemic side effects and enjoy 
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Figure 1. Recommendations for the health professional’s approach to pain management in 
inflammatory arthritis and osteoarthritis (Geenan et al, 2018)
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addition, glucocorticoids and hyaluronic acid 
preparations are among those medications 
used for intra-articular OA therapy.
The current NICE (2014) guidance 
suggests that paracetamol should be offered 
for pain relief in addition to the core 
treatment (exercise). Paracetamol does not 
have the high risk of adverse effects found 
with other potentially more effective options, 
such as NSAIDs or opioids. However, the 
Guideline Development Group highlighted 
that its evidence review relating to the 
effectiveness of paracetamol should be taken 
into account, pending a fuller review of 
pharmacological treatments.
NICE (2014) recommends that alternative 
or additional medication should be considered 
for patients who do not experience adequate 
symptomatic relief with exercise and 
paracetamol or topical NSAIDs. Systemic 
NSAIDs and cyclooxygenase-2 (COX-2) 
inhibitors have been shown to be effective in 
reducing pain and inflammation but they are 
associated with gastrointestinal, liver, kidney 
and cardiovascular side effects ranging from 
mild to severe (Fraenkel and Fried, 2008; 
Al-Omari, 2017). Thus, topical NSAIDs are 
recommended ahead of oral. NSAIDs and 
COX-2 inhibitors may be regarded as a single 
drug class but NICE (2014) continues to use 
the two terms for clarity, and because of the 
differences in the side effect profiles.
Opioid analgesics can be considered to 
treat pain associated with OA (NICE, 2014). 
However, they should be the last choice when 
other medications fail to provide adequate 
pain relief (NICE, 2014)—taking into 
account their risk:benefit profile (Freynhagen 
et al, 2013).
Intra-articular (IA) steroid injections 
offer a potentially useful therapy as it is 
directly targeted at the affected joint with 
few systemic effects. Guidelines produced by 
EULAR (Zhang et al, 2005), the American 
College of Rheumatology (ACR) (Hochberg 
et al, 2012), and Osteoarthritis Research 
Society International (Zhang et al, 2008) also 
recommend their use in the management 
of hip OA. However, as acknowledged by 
the ACR expert panel ‘few trials have been 
performed in patients with symptomatic hip 
OA,’ and their recommendations are based 
on their assessment that ‘patients with hip 
OA should be treated in a similar fashion 
to those with knee OA’ (Hochberg et al, 
2012).Variations in the degree of pain relief 
reported by patients with OA following IA 
corticosteroid injections are well recognised. 
In their systematic review Hirsch et al (2013) 
concluded that previous research had not 
identified reliable predictors of response to 
IA corticosteroid injections, and that further 
studies are required if this question is to be 
answered. McCabe et al (2016) noted that 
international guidelines recommend IA 
steroid injections in the management of hip 
OA, although these recommendations are 
extrapolated primarily from studies of knee 
OA. Their systematic review focused on 
the efficacy of this treatment on pain in hip 
OA. The conclusion was that hip IA steroid 
injections may be efficacious for short-term 
pain reduction in those with hip OA, though 
the quality of the evidence was relatively 
poor. Further large, methodologically 
rigorous trials are required to verify whether 
IA corticosteroids are beneficial and for 
how long.
Surgery
The final choice of treatment is surgical 
interventions such as joint replacement. The 
non-pharmacological treatments for OA are 
recommended at all levels of disease severity, 
whereas surgery is only recommended 
when patients meet certain criteria that 
include prolonged and established functional 
limitation and severe pain with a substantial 
impact on quality of life (NICE, 2014).
Conclusion
OA is a chronic disabling condition that 
still has no cure. Managing OA includes 
pharmacological and non-pharmacological 
treatment to control the disease progress, 
reduce pain and improve mobility. Arthritis 
and its complications can severely impact 
an individual’s health and quality of life. 
With thorough assessment, suitable referrals, 
and appropriate interventions, nurses can 
help patients with OA lead safe, active, and 
optimally independent lives. BJN
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